Tertomotide
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Tertomotide (GV1001, EARPALLTSRLRFIPK) is a 16-amino acid peptide based on the 616‑626 position fragment of human telomerase reverse transcriptase protein (hTERT). It was originally developed as a peptide vaccine for cancer, as it can trigger immune attack against cancer cells which overexpress telomerase, a common mutation found in malignant tumors.[1][2] However, it does not block telomerase activity in healthy tissue and has been found to produce various useful activities in its own right including antiviral,[3] antiinflammatory[4][5] and antidepressant effects, and has been trialled for numerous other medical applications including Alzheimer's disease[6][7][8][9][10][11] as well as its original role in the treatment of cancer.[12]
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C85H146N26O21 |
| Molar mass | 1868.264 g·mol−1 |
| 3D model (JSmol) | |
| |
| |